Irinotecan/floxuridine liposomal

Drug Profile

Irinotecan/floxuridine liposomal

Alternative Names: CPX-1; Floxuridine/irinotecan; Irinotecan HCl:Floxuridine; Irinotecan:Floxuridine; Liposomal irinotecan/floxuridine

Latest Information Update: 11 Aug 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celator Pharmaceuticals
  • Class Antineoplastics; Camptothecins; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA topoisomerase I inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Colorectal cancer

Most Recent Events

  • 13 Aug 2015 Phase-II development is ongoing in USA and Canada
  • 17 Mar 2015 Celator Pharmaceuticals has patent protection for irinotecan/floxuridine in Japan (Celator Pharmaceuticals 10-K, March 2015)
  • 01 Apr 2013 Irinotecan/floxuridine is still in phase II trials for Colorectal cancer (second-line therapy or greater, late-stage disease) in Canada and the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top